Atria Wealth Solutions’s Vaxcyte PCVX Stock Holding History

Atria Wealth Solutions’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$245K	Buy	+7,540	New	+$247K	0.01%	1265

Other funds holding PCVX

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Atria Wealth Solutions's PCVX Position: Q2 2025 in Review

Atria Wealth Solutions opened a new position in Vaxcyte (PCVX) in Q2 2025: 7,540 shares worth $245K. The stake represents 0.01% of the portfolio and ranks #1265 among its holdings.

294 funds tracked by Wall St. Rank hold PCVX as of Q2 2025.

Atria Wealth Solutions held 7,540 shares of Vaxcyte worth $245K as of Q2 2025.
Vaxcyte was a new Atria Wealth Solutions position in Q2 2025.
Vaxcyte made up 0.01% of Atria Wealth Solutions's portfolio in Q2 2025, its #1265 holding.
294 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2025.

Based on Atria Wealth Solutions's 13F filing for Q2 2025, filed 25 Jul 2025.